KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials: |
|
|
|
|
|
|
ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints: |
|
|
|
|
|
|
KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia: |
|
|
|
|
|
|